Related Experiment Videos
Expectant management of clinically localized prostatic cancer
1Urologic Service of Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York.
The Journal of Urology
|November 1, 1994
Summary
This study on prostate cancer found that expectant management of stage B disease often leads to slow progression and long survival. Tumor progression was typically local, with mortality influenced by both cancer and comorbidities.
Area of Science:
- Oncology
- Urology
Background:
- Clinical stage B prostate cancer historically warrants treatment.
- Long-term outcomes for untreated stage B prostate cancer are not well-defined.
Purpose of the Study:
- To evaluate the natural history and outcomes of patients with clinical stage B prostate cancer managed expectantly without immediate therapy.
Main Methods:
- Retrospective analysis of 75 patients with histologically confirmed stage B prostate cancer.
- Patients received no therapy for at least one year post-diagnosis.
- Data collected on tumor progression, metastasis, treatment initiation, and survival.
Main Results:
- Over 90% of progressions were local.
- Median intervals: 78 months to local progression, 186 months to metastasis, 108 months to treatment initiation, 156 months to death.
- Protracted survival was observed, often correlating with tumor progression rates.
Conclusions:
- Expectant management of stage B prostate cancer can result in slow progression and prolonged survival.
- Both prostate cancer itself and comorbid conditions significantly impact mortality in these patients.